Prognostic Factors Predicting Remission Following Rituximab Therapy for Pemphigus Vulgaris
Acta Dermato-Venereologica · 2025
DOI: 10.2340/actadv.v105.27140 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Dermato-Venereologica, 2025. Verfasst von Tal Raviv und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Sheba Medical Center, Tel HaShomer, Ramat Gan, affiliated to the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israe…. Hauptthemen laut MEDLINE: Pemphigus, Rituximab, Remission Induction, Recurrence. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Pemphigus vulgaris is a chronic autoimmune blistering disease with significant morbidity. Rituximab, approved as its first-line treatment, effectively induces remission. However, few studies have analysed the prognostic factors for improved rituximab outcomes. Therefore, this study aimed to identify such factors in a cohort of pemphigus vulgaris patients. A total of 142 pemphigus vulgaris patients treated with rituximab at Sheba Medical Center, with data encompassing demographics, comorbidities, disease characteristics, and treatment outcomes, were retrospectively examined. Results showed that 61.9% of patients previously treated with mycophenolate mofetil achieved partial remission, whereas only 34.7% achieved complete remission. Patients with diabetes mellitus exhibited a significantly shorter median time to relapse compared with those without. Patients with a disease duration ≤ 16 months before rituximab therapy exhibited a shorter median time to relapse. Moreover, previous dapsone treatment extended time to relapse. Notably, sex, age at symptom onset and rituximab therapy, ethnicity, comorbidities, skin involvement, weight, rituximab dosing protocol, and other variables were not statistically significant between the complete remission and partial remission groups. These findings highlight the influence of specific patient characteristics and treatment histories on response to rituximab and time to relapse in pemphigus vulgaris patients. Understanding these factors can aid clinicians in predicting treatment outcomes and selecting the appropriate patient population for rituximab therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Sheba Medical Center, Tel HaShomer, Ramat Gan, affiliated to the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. tal.raviv7@gmail.com.
- Department of Dermatology, Sheba Medical Center, Tel HaShomer, Ramat Gan, affiliated to the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Department of Dermatology, Sheba Medical Center, Tel HaShomer, Ramat Gan, affiliated to the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Institute of Pathology, Sheba Medical Center, Tel HaShomer, Ramat G…
- Department of Dermatology, Sheba Medical Center, Tel HaShomer, Ramat Gan, affiliated to the Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Phototherapy Unit, Department of Dermatology, Sheba Medical Center,…
Zitieren
APA
Raviv, T., Pevzner, K., Barzilai, A., Pavlotsky, F., & Baum, S. (2025). Prognostic Factors Predicting Remission Following Rituximab Therapy for Pemphigus Vulgaris. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v105.27140
Vancouver
Raviv T, Pevzner K, Barzilai A, Pavlotsky F, Baum S. Prognostic Factors Predicting Remission Following Rituximab Therapy for Pemphigus Vulgaris. Acta Dermato-Venereologica. 2025. doi:10.2340/actadv.v105.27140
BibTeX
@article{Raviv2025,
author = {Raviv, Tal and Pevzner, Keren and Barzilai, Aviv and Pavlotsky, Felix and Baum, Sharon},
title = {Prognostic Factors Predicting Remission Following Rituximab Therapy for Pemphigus Vulgaris},
journal = {Acta Dermato-Venereologica},
year = {2025},
doi = {10.2340/actadv.v105.27140}
}
EUVIMED